Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 142 of the 143 references it cites were found in a registry or an index; 49 of the 109 sources its claims cite were checked for support.

Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through

Open access
Gurumoorthy, Narmatha, Nordin, Fazlina, Tye, Gee Jun, Wan Kamarul Zaman, Wan Safwani, Ng, Min Hwei · 2022 · Biomedicines

Abstract

Lentiviral vectors (LVs) play an important role in gene therapy and have proven successful in clinical trials. LVs are capable of integrating specific genetic materials into the target cells and allow for long-term expression of the cDNA of interest. The use of non-integrating LVs (NILVs) reduces insertional mutagenesis and the risk of malignant cell transformation over integrating lentiviral vectors. NILVs enable transient expression or sustained episomal expression, especially in non-dividing cells. Important modifications have been made to the basic human immunodeficiency virus (HIV) structures to improve the safety and efficacy of LVs. NILV-aided transient expression has led to more pre-clinical studies on primary immunodeficiencies, cytotoxic cancer therapies, and hemoglobinopathies. Recently, the third generation of self-inactivating LVs was applied in clinical trials for recombinant protein production, vaccines, gene therapy, cell imaging, and induced pluripotent stem cell (iPSC) generation. This review discusses the basic lentiviral biology and the four systems used for generating NILV designs. Mutations or modifications in LVs and their safety are addressed with reference to pre-clinical studies. The detailed application of NILVs in promising pre-clinical studies is also discussed.

Overview

CoChat Summary

TL;DR

This review argues that non-integrating lentiviral vectors (NILVs) are a safer alternative to integrating lentiviral vectors because they reduce insertional mutagenesis and malignant transformation risk while still supporting transient or episomal expression. It surveys NILV design and applications in vaccination, cell-type differentiation, site-directed integration, and gene therapy, emphasizing that NILVs are especially useful in non-dividing or slowly dividing cells.

Key findings

  • NILVs are designed to avoid genomic integration by mutating integrase or LTR attachment sequences; the paper says this reduces insertional mutagenesis and lets vector DNA persist as non-replicating episomes, especially in non-dividing cells.
  • Compared with other non-integrating methods, the paper states episomal plasmids and Sendai viral (SeV) vectors have the highest efficiency and only occasional integration, while NILVs still have the advantage of broad cell/tissue transduction and higher transfer efficiency in dividing and non-dividing cells.
  • In vaccination, the review reports that a single NILV immunisation encoding West Nile virus envelope induced a strong B-cell response and early, long-lasting protective immunity; another NILV approach against OVA in mice showed complete protection against thymoma.
  • In cell-type differentiation, the paper notes that APOA-II-GFP-positive human embryonic stem cells produced hepatic progenitors with 99% expressing hepatoblast markers, and it highlights iPSC production as a promising but still underused NILV application.

Methods

  • Narrative review of lentiviral biology, NILV design, limitations, and clinical/pre-clinical applications.
  • The paper synthesizes prior studies across pre-clinical and clinical contexts, including vaccination, iPSC generation, site-directed integration, and gene therapy.
  • Main analysis is comparative and descriptive, drawing contrasts among NILVs, integrating lentiviral vectors, and other non-integrating systems such as SeV, episomal plasmids, AAV, and EBV-based approaches.

Limitations

  • The paper states NILVs lose episomes during rapid cell division and therefore have reduced long-term expression in highly proliferative cells.
  • It also states NILVs can show reduced transgene expression compared with integrating vectors, and that residual integration is still not acceptable for some clinical applications.
  • Evident from the text: this is a review, so it does not present a new primary dataset or new experimental results of its own.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biomedicines10010107

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The HIV-1 virus contains three gene regions, gag, pol, and env, along with accessory genes (vif, vpr, vpu, nef), regulatory genes (tat, rev), and the 5′ and 3′ flanking long terminal repeats (LTR). The psi (Ψ) element is located at the 5′ end of the HIV-1 genome just upstream of the gag initiation codon.
Figure 1 The HIV-1 virus contains three gene regions, gag, pol, and env, along with accessory genes (vif, vpr, vpu, nef), regulatory genes (tat, rev), and the 5′ and 3′ flanking long terminal repeats (LTR). The psi (Ψ) element is located at the 5′ end of the HIV-1 genome just upstream of the gag initiation codon.CC BY · PubMed Central
Figure 2 The basic four-generation lentiviral vector plasmid system. The transgene vector is similar for both first- and second-generation lentiviral vectors, while the third-generation lentiviral vectors additionally have a central polypurine tract (cPPT) and woodchuck hepatis virus post-transcriptional response element (WPRE). SIN vectors also replace the U3 region of 3-LTR in both third- and fourth-generation LVs. The packaging vectors differ for the four generations. The first-generation lentiviral vector has all of the accessory genes required for viral replication (vif, vpr, vpu, and nef). In contrast, second-generation lentiviral vectors do not have these accessory proteins in their packaging vector. Third-generation LVs do not have the Tat regulatory protein. The fourth generation is differentiated by the split of the gag/pol and rev sequences into two different cassettes. All four systems contain VSV-G as an envelope vector.
Figure 2 The basic four-generation lentiviral vector plasmid system. The transgene vector is similar for both first- and second-generation lentiviral vectors, while the third-generation lentiviral vectors additionally have a central polypurine tract (cPPT) and woodchuck hepatis virus post-transcriptional response element (WPRE). SIN vectors also replace the U3 region of 3-LTR in both third- and fourth-generation LVs. The packaging vectors differ for the four generations. The first-generation lentiviral vector has all of the accessory genes required for viral replication (vif, vpr, vpu, and nef). In contrast, second-generation lentiviral vectors do not have these accessory proteins in their packaging vector. Third-generation LVs do not have the Tat regulatory protein. The fourth generation is differentiated by the split of the gag/pol and rev sequences into two different cassettes. All four systems contain VSV-G as an envelope vector.CC BY · PubMed Central

Verification

Claims the paper makes

36 Valid · 12 Not valid · 45 Not checked · 47 Own results and interpretations

59 more claims · 14 with their cited sources checked

Create a free account to see all 140 claims and to verify the 19 references still open.

See all claims — free account
  • It may state two separate claims as one. 57
  • Probably not a substantial claim. 27

Create a free account to see these claims.

Citations

Cites

Show all 143 references

Cited by

See all 69

Metadata

Authors
Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H.
Affiliations
  • University Kebangsaan Malaysia Medical Centre (MY)
  • Universiti Sains Malaysia (MY)
  • Department of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, 50603 Kuala Lumpur, Malaysia
Corresponding author
Nordin, Fazlina
Venue
Biomedicines
Publisher
MDPI AG
Published
2022-01-05
Volume
10
Issue
1
Pages
107
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4206000278
Cited by
69
References
143
Citations by year
2026: 7 · 2025: 27 · 2024: 19 · 2023: 10 · 2022: 5
FWCI
2.35
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministry of Higher Education (FRGS/1/2020/SKK06/UKM/03/4)
  • National University of Malaysia (FF-2020-327)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
lentiviral vectors, gene therapy, transient expression, insertional mutagenesis, HIV-based vectors, self-inactivating lentiviral vectors, primary immunodeficiency, hemoglobinopathies, recombinant protein expression, vaccines, induced pluripotent stem cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through. https://app.cochat.ai/papers/10.3390/biomedicines10010107
The paper
Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H. (2022). Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through. Biomedicines. https://doi.org/10.3390/biomedicines10010107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.